Title - ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND TO BCMA AND CD3, AND THEIR USES

Abstract

In addition, the related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, the cells expressing the provided antibodies or antigen-binding fragments, as well as the associated vectors and the detectably labeled antibodies or antigen-binding fragments, are described. Methods for using the provided antibodies are also described. For example, the provided antibodies could be used to diagnose, treat, or monitor the progression, regression, or stability of BCMA-expressing cancer; to determine whether a patient should receive cancer treatment; or to determine whether a subject has BCMA-expressing cancer and, therefore, might be susceptible to treatment with a BCMA-specific anticancer therapeutic agent, such as the multispecific antibodies against BCMA and CD3 described herein.

Claims

1. An isolated recombinant antibody, or an isolated antigen-binding fragment thereof, that binds immunospecifically to B cell maturation antigen (BCMA), characterized in that the antibody has a heavy chain and a light chain, the heavy chain comprising: a. a heavy chain complementarity-determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO.: 4, a heavy chain complementarity-determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO.: 5, and a heavy chain complementarity-determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO.: 6; or b. a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO.: 7, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO.: 5, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO.: 6; or c.a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO.: 4, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO.: 5, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO.: 19; or d. a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO.: 4, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO.: 8, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO.: 6; or e. a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO.: 13, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO.: 5, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO.: 19; or f. a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO.: 13, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO.: 8, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO.: 19 wherein said antibody further comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO.: 24, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO.: 25, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO.:

26. 10 Claims follow.